- NeuroSearch to attend the related launch in the British Parliament of an All
Party Parliamentary Group on Huntington's disease

Copenhagen 30 June 2010 - Today, NeuroSearch A/S (NEUR) informed, an article
published online for The Lancet reveals that prevalence of Huntington's disease
in the UK has been massively underestimated. In fact, official figures for
those who are symptomatic of having Huntington disease are wrong by a factor of
at least two. In the article, Sir Michael Rawlins, Chairman of the British
National Institute for Health and Clinical Excellence (NICE), points out that
the Huntington's Disease Association in the UK currently cares for 6702 people
with HD symptoms, and that from these numbers alone, the minimum prevalence in
England and Wales must therefore be at least 12.4 per 100 000 population,
rather than a previously estimated 6.7 cases per 100 000. The article also
states that the number of people impacted by the disease has been hugely
misjudged.

In the article, Sir Michael Rawlins also explains that the new figure is still
likely to be an underestimate, due to factors such as the possibility that
those affected by the disease may try to hide the true nature of their
symptoms, even from their family doctor, and comments:
"Stigma (of having Huntington's disease) has had a deleterious effect on
studies that have sought to investigate its epidemiology and the true
prevalence is unquestionably greater than this.?

A study investigating the UK prevalence of Huntington's disease is to be
commissioned and will be led by one of the UK's leading epidemiologists,
Professor Stephen Evans. This study will analyse records from GP databases and
is expected to prove that even the updated figure is an underestimate of the
true prevalence of Huntington's disease.

Sir Michael Rawlins' article in The Lancet will accompany an article by Dr
Alice Wexler in the same edition on the stigma attached to Huntington's
disease. A feature in The Lancet Neurology by Laura Spinney on the prevalence
and a clinical review on Huntington's disease by Professor Sarah Tabrizi for
the British Medical Journal are also published today.

At a press conference held to address The Lancet content and its implications,
Dr Nancy Wexler, Higgins Professor of Neuropsychology at the Columbia
University and president of the Hereditary Disease Foundation, explained how
the new revelations about Huntington's disease prevalence in the UK could have
significant ramifications worldwide, as there is reason to suppose the new
statistics would be relevant also to the rest of Europe and the Americas, where
prevalence is assumed to be largely the same as in the UK.

Launch of an All Party Parliamentary Group on Huntington's disease in the UK
Also today, Wednesday 30 June, an All Party Parliamentary Group (APPG) for
Huntington's disease will be launched at the British Parliament. The APPG is
broadly supported by members from both Houses and shall look into the
implications of the new prevalence findings for the provision of disease care
and funds for research.

NeuroSearch has been invited to attend the launch event to take place inside
Parliament today, from 16:00 to 18:00, and will also be represented on the list
of speakers available to the press for interviews in advance of the launch to
explain the crucial nature of the APPG on the outlook for Huntington's disease.

Representing NeuroSearch is Dr. Joakim Tedroff, Neurologist and Head of
Clinical Science at NeuroSearch, who commented:
"Huntington's disease is a progressive neurodegenerative disorder for which
there is an urgent need for new treatments. The new prevalence findings
emphasize the stigma associated with the disease and indicate that the societal
disease burden may be greater than previously thought. Huntexil® from
NeuroSearch has been shown to have the potential to improve the core symptoms
underlying Huntington patients' functional decline and to be well tolerated,
thereby making it a potential therapy for a significant proportion of patients
affected by the disorder."

The launch of the APPG will be celebrated by members of the Huntington's
disease community as a huge step towards improved care for those with the
disease and a big gathering under the banner "HiDden no more" is planned for
outside the Houses of Parliament on the occasion.


NeuroSearch contact persons:

Flemming Pedersen, CEO: +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103

About Huntington's disease
Huntington's disease is a highly disabling, incurable genetic disorder of the
central nervous system, which leads to degeneration of the nerve cells in
certain areas of the brain including the basal ganglia and the cerebral cortex.
The disease is hereditary, and every child of someone with Huntington's disease
has a 50% chance of inheriting the disease.
Patients with Huntington's disease experience a wide variety of symptoms, which
typically can be grouped into three categories: loss of muscle co-ordination
and motor function, cognitive impairment and psychiatric changes. The onset of
symptoms is typically around 35 and 45 years of age, and patients hereafter
deteriorate gradually with a life expectancy of 10 to 20 years.
Patients with Huntington's disease will eventually require full time nursing
care before they die, and the area represents high unmet medical needs. There
is currently no cure or effective treatment available and only a limited number
of novel drugs in development.
The disease is estimated to have a prevalence of about 1: 10 000 in most
western countries, corresponding to an estimated 70 000 affected patients in
North America and Europe combined. In other parts of the world, the disease
prevalence varies substantially among geographic regions and is generally
lower.

About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. The broad drug pipeline comprises eight clinical (Phase I-III)
development programmes, including Huntexil® (pridopidine), a unique orphan
product in Phase III development for the treatment of Huntington's disease, to
which drug NeuroSearch has retained global commercial rights. Also, the company
has tesofensine ready for Phase III development as a novel treatment of
obesity. The company also has a broad portfolio of preclinical drug candidates
and strategic drug discovery alliances with Janssen Pharmaceutica and Eli Lilly
and Company as well as a licence collaboration with Abbott. Further,
NeuroSearch holds equity interests in a number of private health care
companies.